IBCSG 59-19 POLAR

  • A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer

    Palbociclib for HR positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

  • Study Co-Chairs
    Elisabetta Munzone, MD, Milan, Italy
    Prof. Stefan Aebi, MD, Lucerne, Switzerland

    Statistician
    Meredith Regan, Yue Ren

    Trial Coordinator
    Dorene Polizzi

    Data Manager
    Adriana Karausch, Dorene Polizzi

    IBCSG Data Management Center/Frontier Science Foundation
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email:
    This email address is being protected from spambots. You need JavaScript enabled to view it.


    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    June 25, 2019

    Targeted Accrual
    400

    Protocol Release Date 
    December 07, 2018

    Trial Activation Date 
    June 25, 2019

    First Patient In 
    August 27, 2019

    Accrual Closure Date 
    January 31, 2025

    Global Trial Completion Date
    N/A

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login